Skip to content. | Skip to navigation

News
>
Roundtable l Prefilled Syringes & Parenteral Contract Manufacturing

Roundtable l Prefilled Syringes & Parenteral Contract Manufacturing

Medium: Drug Development & Delivery

Overall world revenue for prefilled syringes is expected to grow rapidly through 2020 thanks to increasing demand for chronic disease treatment, market entry of biologics and biosimilars, and innovative prefilled injection devices. And while glass continues to remain the gold standard for prefilled syringes, the proportion of plastic-based prefilled syringes is expected to increase, too due to concerns of glass breakage and plunger failure. What are the key factors that drive this rapid update of prefilled syringes? And what are the specific requirements that need to be adressed in the future?   

Prefilled syringes are simple compared with a traditional syringe and vial. The products reduce the number of steps required for drug administration while improving safety by reducing the potential for drug contamination, needlestick injuries and dosing errors. An increasing incidence of chronic disease means patients are requiring injectable drugs to self-dose at home, which is much easier and safer with prefills. A number of prefilled syringe manufacturers have developed dual- and multi-chambered syringes, to cater to drugs that must be reconstituted at the point of delivery. Find out more about the factors that drive the rise of prefilled syringes in the full Drug Development & Delivery report. It features several of the players in the prefilled syringe and parenteral manufacturing market including Vetter highlighting the issues of traceability and customization.  

Roundtable  
Prefilled Syringes & Parenteral Contract Manufacturing: Anticipating the Needs of the Future

Back to newsroom